You are on page 1of 5

Hendriks et al.

BMC Musculoskeletal Disorders 2014, 15:346


http://www.biomedcentral.com/1471-2474/15/346

RESEARCH ARTICLE Open Access

Type 2 diabetes seems not to be a risk factor for


the carpal tunnel syndrome: a case control study
Steven H Hendriks1*, Peter R van Dijk1, Klaas H Groenier1,2, Peter Houpt3, Henk JG Bilo1,4 and Nanne Kleefstra1,4,5

Abstract
Background: Previous studies have shown that the carpal tunnel syndrome seems to occur more frequently in
patients with diabetes mellitus and might be associated with the duration of diabetes mellitus, microvascular
complications and degree of glycaemic control. Primary aim was to determine if type 2 diabetes can be identified
as a risk factor for carpal tunnel syndrome after adjusting for possible confounders. Furthermore, the influence of
duration of diabetes mellitus, microvascular complications and glycaemic control on the development of carpal
tunnel syndrome was investigated.
Methods: Retrospective, case–control study using data from electronic patient charts from the Isala (Zwolle, the
Netherlands). All patients diagnosed with carpal tunnel syndrome in the period from January 2011 to July 2012
were included and compared with a control group of herniated nucleus pulposus patients.
Results: A total of 997 patients with carpal tunnel syndrome and 594 controls were included. Prevalence of
type 2 diabetes was 11.5% in the carpal tunnel syndrome group versus 7.2% in the control group (Odds
Ratio 1.67 (95% confidence interval 1.16-2.41)). In multivariate analyses adjusting for gender, age and body
mass index, type 2 diabetes was not associated with carpal tunnel syndrome (OR 0.99 (95% CI 0.66-1.47)).
No differences in duration of diabetes mellitus, microvascular complications or glycaemic control between
groups were detected.
Conclusion: Although type 2 diabetes was more frequently diagnosed among patients with carpal tunnel
syndrome, it could not be identified as an independent risk factor.
Keywords: Carpal tunnel syndrome, Type 2 diabetes mellitus, Risk factor

Background are identified as the main risk factors for CTS [1]. In
Carpal tunnel syndrome (CTS) is one of the most fre- addition, diabetes mellitus (DM) is also considered as a
quent compression neuropathies of the upper limb [1]. risk factor [3-7]. Furthermore some researchers found a
Due to entrapment of the median nerve between the higher incidence of CTS in patients with pre-diabetes [8],
flexor tendons of the hand in the carpal tunnel symp- nevertheless screening for DM in patients with CTS is not
toms, like tingling and noctural burning pain, occur [1]. recommended [9]. Literature suggests also a relationship
The combination of these clinical symptoms together between HbA1c, duration of DM, microvascular compli-
with positive signs by physical examination and nerve cations and CTS [10-12]. However, many studies investi-
conduction studies (NCS) is the most valid way of diag- gated DM as a risk factor for musculoskeletal disorders of
nosing CTS [1]. the hand and shoulder in general and not for CTS in par-
The prevalence of CTS in the general population is ticular [11,13].
approximately 2.1% for men and 3.0% for women [2]. Aim of the present study was to determine if type 2
Obesity, hypothyroidism, pregnancy, rheumatoid arthritis, diabetes mellitus (T2DM) can be identified as a risk
osteoarthritis and occupational factors like repetitive work factor for CTS. Furthermore, we investigated the influence
of diabetes duration, glycaemic control and presence of
microvascular complications on the development of CTS.
* Correspondence: s.hendriks@isala.nl
1
Diabetes Centre, Isala, Zwolle, the Netherlands
Full list of author information is available at the end of the article

© 2014 Hendriks et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Hendriks et al. BMC Musculoskeletal Disorders 2014, 15:346 Page 2 of 5
http://www.biomedcentral.com/1471-2474/15/346

Methods type of treatment provided. CTS patients were identified


Study population and design using codes 0304.350, 0304.351 and 0330.0801 and HNP
This study was conducted at the Isala, a general hospital patients using the codes 0308.2530, 0308.2550, 0308.2555.
with a catchment area of 800.000 inhabitants in the The DTC codes for DM and diabetic retino-pathie were
North East of the Netherlands. All patients with severe used to identify patients with T2DM who are treated in
symptoms of CTS or with symptoms which could not our clinic.
be treated by a general practitioner with a conservative Demographic and clinical data of the CTS and HNP pa-
approach (i.e. watchful waiting, a brace or corticoster- tients treated in the Isala was derived from the individual
oid injections) and who were referred to the outpatient electronic patient database of the Isala. Furthermore this
clinic of the Isala between January 2011 and July 2012 database was used to verify the CTS and HNP diagnoses.
were identified. The diagnosis CTS was defined as the The diabetes specific database of our Diabetes Centre was
presence of classical symptoms for CTS consisting of used for identifying and further detailing of information
nocturnal pain associated with tingling and numbness regarding patients with T2DM who are treated in primary
in the distribution of median nerve in the hand. Patients care. General practitioners in our region, receive bench
were only included when NCS were performed during the mark information from our Diabetes Centre and therefore
diagnostic process of CTS, irrespective of the outcome of we gather data of all primary care treated patients with
the NCS. NCS were executed by a neurologist and con- T2DM on a yearly basis. This database is used in our
sisted of 1 motor and 2 sensory conduction tests. A com- Diabetes Centre for study purposes. Permission to use the
parison was made of the distal motor latencies from the CTS and HNP related data was given by de data manage-
median nerve to the second lumbrical and from the ulnar ment centre of the Isala.
nerve to the second interosseous muscle with equal dis-
tances. Furthermore, a comparison was made of the sen- Variables
sory conduction of the median nerve with the ulnar nerve Age, gender, body mass index (BMI) and blood pressure
between wrist and digit 4 and of the sensory conduction were documented for all patients. Date of CTS diagnosis,
of the median with the radial nerve between wrist and CTS side, result of nerve conduction studies and type of
thumb. If two of three tests were abnormal, the diagnosis treatment were recorded in the database for CTS patients.
of CTS was electrophysiologically confirmed. All nerve Duration of DM, types of medication, HbA1c, renal func-
conduction studies were performed with a Synergy system tion and the occurrence of albuminuria, retinopathy and
of Viasys Healthcare from 2005 without controlling for neuropathy were documented for all T2DM patients.
the hand temperature. Patients with an (ipsi and/or
contralateral) recidive of a previous CTS were excluded. Outcome
In order to compare the prevalence of T2DM among Primary outcome was the prevalence of T2DM in both
patients with CTS with the general population, a control groups. Secondary outcomes were duration of DM, micro-
group was formed consisting of operatively treated herni- vascular complications (albuminuria, retinopathy and
ated nucleus pulposus (HNP) patients. HNP patients were neuro-pathie together) and glycaemic control in relation to
chosen assuming that HNP patients would be derived CTS development.
from about the same age category as the CTS group and
because it is a frequently diagnosed disease which makes Statistical analysis
it possible to build a control group consisting of enough Statistical analysis was carried out in SPSS (version 20)
patients. Finally only operated patients were chosen be- using logistic regression, adjusting for confounding vari-
cause DM status and BMI data are known for the majority ables. Multiple imputation (10 imputed datasets) was used
of operated patients in our hospital. Patients in the control for missing BMI values. The sample size required for the
group were treated in the same period as the CTS group. control group to detect a difference in T2DM prevalence
They were excluded when they received an operation of 5%, assuming a CTS group size of 900 patients, a power
because of a relapse or had received the diagnosis CTS of 0.8, and an alpha of 0.05 was 459.
in the past.
Ethical approval
Data sources This study is performed in accordance with the Declar-
Patients, both CTS cases and the HNP controls, were ation of Helsinki. According to Dutch guidelines this
identified using diagnosis-treatment-combination (DTC) research does not fall under the scope of the Medical
codes, which are used in the Netherlands for both hospital Research Involving Human Subjects Act, and therefore
registration and health insurance declaration purposes. this study does not need a formal approval of an accre-
Each DTC code contains information about the specialty dited METC (The Medical Ethics Committee of the
of the treating physician, the patient’s diagnosis and the Isala).
Hendriks et al. BMC Musculoskeletal Disorders 2014, 15:346 Page 3 of 5
http://www.biomedcentral.com/1471-2474/15/346

Results Secondary outcomes


A total of 1482 patients with a DTC for CTS and 765 Analyses of the subgroups with T2DM are also displayed
patients with a DTC for HNP were identified of which in Table 1. The CTS group contained 115 patients with
485 CTS patients and 171 HNP controls did not meet the T2DM versus 43 patients with T2DM in the control
inclusion criteria (Figure 1). Eventually, 997 persons with group. Patients in the CTS group were significantly older
CTS and 594 controls were included. and had a higher BMI. Duration of DM, presence of
microvascular complications and glycaemic control did
Primary outcome not differ between the two groups.
The results of the univariate analyses are presented in
Table 1. The prevalence of T2DM was 11.5% in the CTS Discussion
group and 7.2% in the control group (Odds Ratio (OR) In this study we investigated the relationship between
1.67 (95% confidence interval (CI) 1.16-2.41)). The per- T2DM and CTS. Although T2DM was more frequently
centage of female patients was significantly higher in the diagnosed among patients with CTS, it could not be
CTS group compared with the control group (OR 2.54 identified as a risk factor after adjusting for BMI, gender
(95% BI 2.06-3.14), p <0.001). The mean age was 55.7 and age. However, BMI, gender and age remained having
(±15.2) years in the CTS group and 49.3 (±13.0) years in a relationship with CTS. No associations were found be-
the control group (p <0.001). Furthermore, the mean BMI tween the duration of DM or microvascular complica-
was also higher in the CTS group (p <0.001). tions and CTS. In addition, as demonstrated previously,
Five hundred sixty-seven (56.9%) patients had a bilateral we were unable to find a relationship between glycaemic
CTS and 430 patients had an unilateral CTS of whom 252 control and CTS development [11].
(58.6%) right-sided. In 921 (92.4%) subjects diagnosis was This is the first study to investigate the relation between
confirmed by NCS. Treatment consisted in 18.3% of con- CTS and T2DM in a secondary care setting. Strengths of
servative treatment, in 78.1% of operation and was not this study include the use of different data sources to over-
well documented in 3.6% of the patients. Four hundred come limitations of the retrospective design (i.e. misclassi-
twenty-one patients in the control group had a herniated fication of CTS diagnosis and missing data). In addition,
disc at the lumbar spine level and 173 patients had a her- the use of different data sources enabled us to make a cer-
niated disc at the cervical level. tain diagnosis of CTS and T2DM.
Table 2 displays the results of the multivariate analyses. Several limitations should be mentioned. First, cases
In model 1 (adjusting for gender) and in model 2 (adjust- and controls were only enrolled in a secondary care set-
ing for both gender and BMI) T2DM was a significant ting and thereby mostly severe cases were included.
predictor for CTS. However, when age was added (model 3), Thus, less severe CTS patients treated with conservative
T2DM disappeared as a significant predictor (OR 0.99 treatment by general practitioners did not participate in
(95% BI 0.66-1.47)). Gender, BMI and age remained the current study. Therefore the generalizability of our
significant predictors for CTS in this final model. The results is limited to secondary care. In addition, external
same results were obtained when only patients with validity is also limited due to the fact that the studied
CTS confirmed by nerve conduction studies were in- population consisted of only ~1% of the DM and ~11%
cluded (data not shown). of the CTS patients of the total amount of DM and CTS

Figure 1 Flowchart inclusion.


Hendriks et al. BMC Musculoskeletal Disorders 2014, 15:346 Page 4 of 5
http://www.biomedcentral.com/1471-2474/15/346

Table 1 Results of univariate analyses between the CTS group and the control group
Variables CTS group Control group p-value OR (95% CI)
(n =997) (n =594)
T2DM 115 (11.5) 43 (7.2) 0.006 1.67 (1.16-2.41)
Gender (female) 710 (71.2) 293 (49.3) <0.001 2.54 (2.06-3.14)
Age (years) 55.7 ± 15.2 49.3 ± 13.0 <0.001 1.03 (1.02-1.04)
BMI (kg/m2)a 28.3 ± 5.4 26.7 ± 4.6 <0.001 1.06 (1.04-1.09)
Systolic RR (mmHg) 138.8 ± 21.4 138.6 ± 20.6 0.870 1.00 (0.99-1.01)
Age DM patients (years) 65.6 ± 12.7 60.1 ± 13.7 0.021 1.03 (1.01-1.06)
Gender DM patients (female) 74 (64.3%) 21 (48.8%) 0.078 1.89 (0.93-3.84)
BMI DM patients (kg/m2) 31.2 ± 5.7 29.1 ± 5.1 <0.001 1.07 (1.04-1.10)
Median diabetes duration (months)b 103 (55–172) 80 (47–166) 0.389 1.00 (1.00-1.01)
c
HbA1c (% (mmol/mol)) 7.1 ± 3.2 (54 ± 11) 7.3 ± 3.2 (56 ± 12) 0.567 0.99 (0.95-1.03)
Microvascular complicationsd 46 (40.0%) 13 (30.2%) 0.402 0.68 (0.28-1.67)
Metformin 69 (60.0%) 26 (60.5%) 0.582 1.15 (0.70-1.89)
SU-derivate 34 (29.6%) 7 (16.3%) 0.09 2.19 (0.89-5.40)
Insulin 52 (45.2%) 18 (41.9%) 0.673 1.17 (0.57-2.37)
Values are depicted as number (%), mean ± SD or median with 25th and 75th percentile.
a
Imputation was used for 229 patients with a missing value for BMI in the CTS group and for 12 controls.
b
2 missing values in the CTS group and 16 in the control group.
c
6 missing values in the CTS group and 20 in the control group.
d
12 missing values in the CTS group and 19 the control group.

patients in our region. Moreover, although both the op- consultation. The choice to use surgery-treated HNP pa-
erated CTS and HNP patients had the same kind of pre- tients as a control population is also a topic for debate.
operative screening in which the presence of DM was Smaller studies have described a relationship between
assessed, we cannot exclude the possibility of more in- DM and HNP, so although inconclusive, the prevalence
tensive screening in one of the two groups which may of T2DM could be higher among these persons than in
have resulted in a different DM prevalence within and the general population [14]. Additionally, as overweight
between the two groups. Furthermore, differential mis- is identified as a risk factor for the occurrence of lumbar
classification bias could have occurred because conser- disc herniation, and overweight is also is a major risk
vatively treated CTS patient have had no preoperatively factor for T2DM, this could have resulted in a higher
prevalence of DM in the HNP population compared
Table 2 Multivariate analysis of T2DM as an risk factor with the general population [15,16]. Therefore, shared
for CTS adjusting for gender, age and BMI risk factors, such as BMI, should be taken into account
model (n =1591) B p-value OR (95% CI) when interpreting the results of our study. At last, it
Model 1 should be noticed that, due to the amount of missing
T2DM 0.571 0.003 1.77 (1.22-2.58) data any relevant relationships cannot be excluded based
Gender a
0.945 <0.001 2.57 (2.08-3.18) on the present study.
Similar to our results, a study among 156 CTS patients
Model 2
and 473 age and sex matched controls derived from a
T2DM 0.389 0.048 1.48 (1.00-2.17)
Dutch population register could not find a relation be-
Gendera 0.953 <0.001 2.59 (2.09-3.22) tween DM and CTS [17]. Furthermore, a study from
b
BMI 0.060 <0.001 1.06 (1.04-1.09) Greece found an identical prevalence of DM in a CTS
Model 3 population as compared to control subjects from the gen-
T2DM −0.014 0.946 0.99 (0.66-1.47) eral population [18]. On the other hand a significant rela-
tion was found in a larger cohort of 3391 CTS patients
Gendera 0.976 <0.001 2.65 (2.13-3.31)
and 13.564 matched controls (OR 1.51 (95% BI 1.24-1.84))
Age 0.034 <0.001 1.03 (1.03-1.04)
[4]. A systematic review indicated DM as a risk factor for
BMIb 0.064 <0.001 1.07 (1.04-1.09) CTS (OR 2.2 (95% BI 1.5-3.1)) [3]. However, not all stud-
B = coefficient of logistic regression.
a
ies included in this review controlled for age differences in
Male gender is reference category.
b
Imputation was used for 229 patients with a missing value for BMI in the CTS
multivariate models, which was found to be an important
group and for 12 controls. confounding variable in the present study.
Hendriks et al. BMC Musculoskeletal Disorders 2014, 15:346 Page 5 of 5
http://www.biomedcentral.com/1471-2474/15/346

Taken together, it could be hypothesized that BMI and 6. Karpitskaya Y, Novak CB, Mackinnon SE: Prevalence of smoking, obesity,
age, both well known risk factors for T2DM, are import- diabetes mellitus and thyroid disease in patients with carpal tunnel
syndrome. Ann Plas Surg 2002, 48:269–273.
ant risk factors for CTS as well, and may explain the rela- 7. Tseng CH, Liao CC, Kuo CM, Sung FC, Hsieh DPH, Tsai CH: Medical and
tionship found between T2DM and CTS in other studies. non-medical correlates of carpal tunnel syndrome in a Taiwan cohort of
Despite the limitations of the present study, i.e. choice of one million. Eur J Neurol 2012, 19:91–97.
8. Gulliford MC, Latinovic R, Charlton J, Hughes RAC: Increased incidence of
control group, limited generalizability due to the second- carpal tunnel syndrome up to 10 years before diagnosis of diabetes.
ary setting, magnitude of missing data and small sample Diabetes Care 2006, 29:1929–1930.
size, this is a hypothesis worth further testing. 9. De Rijk MC, Vermeij FH, Suntjens M, Van Doorn PA: Does a carpal tunnel
syndrome predict an underlying disease? J Neurol Neurosurg Psychiatry
2007, 78:635–637.
Conclusion 10. Singh R, Gamble G, Cundy T: Lifetime risk of symptomatic carpal tunnel
syndrome in Type 1 diabetes. Diabet Med 2005, 22:625–630.
Although type 2 diabetes was more frequently diagnosed 11. Ramchurn N, Mashamba C, Leitch E, Arutchelvam V, Narayanan K, Weaver J,
among patients with carpal tunnel syndrome, it could not Hamilton J, Heycock C, Saravanan V, Kelly C: Upper limb musculoskeletal
be identified as an independent risk factor. BMI and age, abnormalities and poor metabolic control in diabetes. Eur J Intern Med
2009, 20:718–721.
which are well known risk factors for T2DM, are import- 12. Perkins BA, Olaleye D, Bril V: Carpal tunnel syndrome in patients with
ant risk factors for CTS as well and may confound the diabetic polyneuropathy. Diabetes Care 2002, 25:565–569.
previously found relationship between type 2 diabetes and 13. Chammas M, Bousquet P, Renard E, Poirier JL, Jaffiol C, Allieu Y: Dupuytren’s
disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus.
CTS. J Hand Surg Am 1995, 20:109–114.
14. Sakellaridis N: The influence of diabetes mellitus on lumbar intervertebral
Abbreviations disk herniation. Surg Neurol 2006, 66:152–154.
CTS: Carpal tunnel syndrome; DM: Diabetes mellitus; T2DM: Type 2 diabetes 15. Saftic R, Grgic M, Ebling B: Case–control study of risk factors for lumbar
mellitus; NCS: Nerve conduction studies; HNP: Herniated nucleus pulposus; intervertebral disc herniation in Croatian island populations. Croat Med J
DTC: Diagnosis-treatment-combination; BMI: Body mass index; OR: Odds ratio; 2006, 47:593–600.
CI: Confidence interval. 16. Shiri R, Lallukka T, Karppinen J, Viikari-Juntura E: Obesity as a risk factor for
sciatica: a meta-analysis. Am J Epidemiol 2014, 179:929–937.
17. De Krom MC, Kester AD, Knipschild PG, Spaans F: Risk factors for carpal
Competing interests
tunnel syndrome. Am J Epidemiol 1990, 132:1102–1110.
All authors declare that they have no competing interests.
18. Stamboulis E, Vassilopoulos D, Kalfakis N: Symptomatic focal
mononeuropathies in diabetic patients: increased or not? J Neurol 2005,
Authors’ contributions 252:448–452.
SHH (guarantor), PRD, KHG, PH, HJGB and NK designed the study; SHH and
PRD acquired the data used in this study; SHH, PRD and NK analysed the doi:10.1186/1471-2474-15-346
data; SHH and KHG performed the statistical analyses; SHH and PRD drafted Cite this article as: Hendriks et al.: Type 2 diabetes seems not to be a
the manuscript. SHH, PRD, KHG, PH, HJGB and NK participated in risk factor for the carpal tunnel syndrome: a case control study. BMC
interpretation of the data and in revision of the manuscript. All authors read Musculoskeletal Disorders 2014 15:346.
and approved the final manuscript. PRD, NK and HJGB supervised the study.

Acknowledgements
Steven H. Hendriks is the guarantor of this work and, as such, had full access
to all the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.

Author details
1
Diabetes Centre, Isala, Zwolle, the Netherlands. 2Department of General
Practice, University of Groningen, Groningen, the Netherlands. 3Department
of Plastic Surgery, Isala, Zwolle, the Netherlands. 4Department of Internal
Medicine, University of Groningen, Groningen, the Netherlands. 5Langerhans,
Medical Research Group, Zwolle, the Netherlands.

Received: 25 February 2014 Accepted: 3 October 2014


Published: 14 October 2014

References Submit your next manuscript to BioMed Central


1. Aroori S, Spence RAJ: Carpal tunnel syndrome. Ulster Med J 2008, 77:6–17. and take full advantage of:
2. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I:
Prevalence of carpal tunnel syndrome in a general population. JAMA
• Convenient online submission
1999, 282:153–158.
3. Van Dijk MAJ, Reitsma JB, Fischer JC, Sanders GTB: Indications for • Thorough peer review
requesting laboratory tests for concurrent diseases in patients with • No space constraints or color figure charges
carpal tunnel syndrome: a systematic review. Clin Chem 2003,
• Immediate publication on acceptance
49:1437–1444.
4. Geoghegan JM, Clark DI, Bainbridge LC, Smith C, Hubbard R: Risk factors in • Inclusion in PubMed, CAS, Scopus and Google Scholar
carpal tunnel syndrome. J Hand Surg Br 2004, 29:315–320. • Research which is freely available for redistribution
5. Becker J, Nora DB, Gomes I, Stringari FF, Seitensus R, Panosso JS, Ehlers JAC:
An evaluation of gender, obesity, age and diabetes mellitus as risk
factors for carpal tunnel syndrome. Clin Neurophysiol 2002, 113:1429–1434. Submit your manuscript at
www.biomedcentral.com/submit

You might also like